In addition, although mutated p53 is associated with resistance to conventional anticancer therapies and is considered to be a poor prognostic factor for outcome in cancer patients [21], studies suggest a direct correlation between mutated p53 and in vitro sensitivity to YondelisTM. The gene discussed is TP53; the disease is cancer.